Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

Group 4 tumours (MB(Grp4)) represent the majority of non-WNT/non-SHH medulloblastomas. Their clinical course is poorly predicted by current risk-factors. MB(Grp4) molecular substructures have been identified (e.g. subgroups/cytogenetics/mutations), however their inter-relationships and potential to...

Descripción completa

Detalles Bibliográficos
Autores principales: Goddard, Jack, Castle, Jemma, Southworth, Emily, Fletcher, Anya, Crosier, Stephen, Martin-Guerrero, Idoia, García-Ariza, Miguel, Navajas, Aurora, Masliah-Planchon, Julien, Bourdeaut, Franck, Dufour, Christelle, Ayrault, Olivier, Goschzik, Tobias, Pietsch, Torsten, Sill, Martin, Pfister, Stefan M., Rutkowski, Stefan, Richardson, Stacey, Hill, Rebecca M., Williamson, Daniel, Bailey, Simon, Schwalbe, Edward C., Clifford, Steven C., Hicks, Debbie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119222/
https://www.ncbi.nlm.nih.gov/pubmed/37014508
http://dx.doi.org/10.1007/s00401-023-02566-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119222/
https://www.ncbi.nlm.nih.gov/pubmed/37014508
http://dx.doi.org/10.1007/s00401-023-02566-0

Ejemplares similares